Yamada, A.; Sakurai, Y.; Nakamura, K.; Hanyu, F.; Yoshida, M.; Kaetsu, I. published an article in 1980, the title of the article was The anticancer drug capsule with controlled-release for a long time and change of release rate.Safety of 2,2-Dimethylpropane-1,3-diyl bis(2-methylacrylate) And the article contains the following content:
The capsule was prepared containing mitomycin-C (I) [50-07-7], poly(Me methacrylate) [9011-14-7], together with glass-forming monomers. The capsule was irradiated with 1 × 106 rad γ-ray. The capsule when located around or in inoperable malignant tumor, caused no severe secondary effects like leukopenia. Changing the volume of anticancer drug, amount of γ-irradiation, and kind of monomer, the release period could be extended from 2-4 wk to 140 days. The experimental process involved the reaction of 2,2-Dimethylpropane-1,3-diyl bis(2-methylacrylate)(cas: 1985-51-9).Safety of 2,2-Dimethylpropane-1,3-diyl bis(2-methylacrylate)
The Article related to neoplasm inhibitor capsule controlled release, Pharmaceuticals: Prosthetics and Medical Goods and other aspects.Safety of 2,2-Dimethylpropane-1,3-diyl bis(2-methylacrylate)
Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics